Neurogene Inc (NGNE): Market Cap to Revenue Ratio
Neurogene Inc. utilizes certified international cold chains for the delivery of biocomponents. The scientific team's flexibility is ensured by outsourcing production and testing to external contractors. In-house facilities in Texas and New York guarantee the stability of development. The price-to-sales valuation reflects the price action, where 325.50 determines the current value of the metric.
Metric breakdowns and analytics for Neurogene Corp (NGNE)
- current quotes and average value forecast:
- stock exchange capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Neurogene Inc.|NGNE - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Neurogene Therapeutics|NGNE - Company Aggregate Debts|Debt to Book Value Neurogene Corp|NGNE - Company Long-Term Liabilities|Short-Term Debt Volume Neurogene|Immediate Liquidity Ratio neurogene.com
- earnings and multiples data:
NGNE - Net Profit|Projected Net Profit Neurogene Inc.|NGNE - Price to Earnings Ratio|Price to Future Earnings Ratio Neurogene Inc|NGNE - PEG Multiple|Company Value to EBITDA Neurogene Corp|NGNE - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Neurogene|NGNE - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months neurogene.com|NGNE - Net earnings per share growth this year|Earnings growth forecast for next year Neurogene Inc.
- sales revenue and business income indicators:
General company analysis:NGNE (neurogene.com)
To assess long-term overpayment risks for the investor, it is essential to analyze the P/S ratio, which compares the market capitalization of Neurogene Inc. (NGNE) to its annual revenue, identifying phases of market overheating through revenue multiple dynamics. This indicator allows for the correlation of business value with actual earnings, which is critical for a company whose stability is supported by independent research and production facilities in New York and Texas.
Who Neurogene Inc. competes with
BIIB - Price to Sales|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC: Market Cap to Revenue Ratio|Axsome Therapeutics Inc - P/S Multiple|Price to Sales ACADIA Corp|XENE (Xenon Pharmaceuticals) - Market Cap to Revenue|vikingtherapeutics.com - Market Capitalization-to-Revenue Ratio|SUPN (Supernus) - P/S Multiple|Catalyst Pharma (CPRX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|Harmony Corp - Market Cap to Revenue Ratio|P/S Multiple BHVN (Biohaven Ltd.)|AMLX - Market Cap to Revenue|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Precision Medicines Inc PRAX|Anavex Corp (AVXL) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CBLL|PRTA (Prothena Biosciences) - P/S Multiple|ALEC - Price-to-Revenue Multiple|Price-to-Revenue Ratio Annexon (ANNX)|omeros.com - Market Cap to Revenue Ratio|P/S Multiple ACIU (AC Immune Corp)|Voyager Corp (VYGR) - Price to Sales|NMRA - Price-to-Revenue Ratio|SCLX (scilexholding.com) - Market Cap to Revenue Ratio|TVGN: P/S Multiple|Price to Sales Alpha Cognition Inc. (ACOG)|Market Cap to Revenue CGTX|P/S Multiple Inhibikase Pharma|Price-to-Revenue Ratio Cassava Sciences, Inc. (SAVA)|ASRT (assertiotx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Coya Therapeutics COYA|VistaGen Therapeutics, Inc. (VTGN) - Price to Sales|OVID - Price-to-Revenue Ratio|ABOS (Acumen Pharmaceuticals, Inc) - Market Cap to Revenue Ratio|CRVO: P/S Multiple|Price to Sales Alterity Therapeutics Limited (ATHE)|Market Cap to Revenue CLNN|P/S Multiple PepGen Corp|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|RLMD (Relmada Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Annovis Bio, Inc. ANVS|Grace Therapeutics Inc (GRCE) - Price to Sales|Firefly Neuroscience - P/S Multiple|Price-to-Revenue Multiple Klotho Neurosciences Inc (KLTO)|NRSN: P/S Multiple|Price to Sales Reviva Pharmaceuticals, Inc. (RVPH)|Price-to-Revenue Ratio MetaVia Inc.|Market Cap to Revenue Ratio NRXS (neuraxis.com)|P/S Multiple HSDT|PASG - Price to Sales|Neuphoria Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio NERV|Athira Pharma, Inc. - P/S Multiple|Price-to-Revenue Coefficient addextherapeutics.com ADXN|alzamend.com (ALZN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CYCN|PTIX (Protagenic Therapeutics Inc.) - P/S Multiple|Market Cap to Revenue Pasithea (KTTA)|Market Cap to Revenue CRGT (Cortigent, Inc.)|Price-to-Revenue Coefficient avenuetx.com|Price-to-Revenue Ratio BrainStorm Cell Therapeutics BCLI|CARA: Market Cap to Revenue Ratio|Chromocell Therapeutics Corporation - P/S Multiple|Price-to-Revenue Multiple Eliem Therapeutics (ELYM)|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|Price to Sales NKGen Biotech Inc NKGN|Price-to-Revenue Ratio NeuroBo (NRBO)|Sage Therapeutics Inc - Market Cap to Revenue Ratio|P/S Multiple SNPX (Synaptogenix, Inc.)|trevena.com (TRVN) - Price to Sales|VIGL: Market Cap to Revenue|WENA - P/S Multiple|Cerevel (CERE) - Price-to-Revenue Ratio
